Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
17.99
-0.79 (-4.21%)
Jan 16, 2026, 4:00 PM EST - Market closed
Denali Therapeutics Employees
Denali Therapeutics had 422 employees as of December 31, 2024. The number of employees decreased by 23 or -5.17% compared to the previous year.
Employees
422
Change (1Y)
-23
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,181,858
Market Cap
2.81B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Dec 31, 2020 | 291 | 30 | 11.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNLI News
- 4 days ago - Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 19 days ago - The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewsWire
- 5 weeks ago - Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment - Seeking Alpha
- 5 weeks ago - Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript - Seeking Alpha
- 6 weeks ago - Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - GlobeNewsWire
- 6 weeks ago - Denali: Regulatory Delay Is A Strategic Opportunity - Seeking Alpha